Benchmark raised the firm’s price target on Halozyme to $60 from $50 and keeps a Buy rating on the shares to reflect increased guidance for revenues and earnings this year as well as recent progress from R&D partners.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
Questions or Comments about the article? Write to editor@tipranks.com